{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'recommendation after consideration of the OS results and other supportive evidence', 'including other relevant efficacy and safety data.', 'Details for the futility analysis will be provided in the IDMC charter.', 'Section 8.6 Accrual/Study Duration Considerations', 'Last sentence previously read:', 'It is projected that 480 subjects with DLL3 high will have enrolled for the interim analysis', 'by the time at least 407 PFS events per CRAC and at least 239 OS events should be', 'observed in subjects with DLL3high and subjects have completed approximately 5 months', 'of follow-up.', 'Has been changed to read:', 'It is projected that 480 subjects with DLL3 high ED SCLC will have enrolled for the', 'primary analysis by the time approximately 420 PFS events per CRAC and at least 319', 'OS events should be observed in DLL3 high subjects after approximately 8 - 10 months of', 'follow-up.', 'Section 10.1 Source Documents', 'First paragraph, fourth and fifth sentence previously read:', 'The Investigator Awareness Date (SAE CRF) may serve as the source for this data point.', 'This adverse event data point required for eCRF completion can be entered directly in the', 'eCRF.', 'Has been changed to read:', 'The Investigator Awareness Date of SAE should be noted in the source.', '201']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 15.0 References', 'Add: new Reference 19', 'AbbVie. Rovalpituzumab Tesirine Dear Rova-T Investigator Letter. 05 December 2018.', 'Appendix B. List of Protocol Signatories', 'Previously read:', 'Name', 'Title', 'Functional Area', 'Clinical', 'Clinical', 'Clinical', 'Pharmacokinetics', 'Clinical Drug Supply Management', 'Statistics', 'Bioanalysis', 'Has been changed to read:', 'Name', 'Title', 'Functional Area', 'Clinical', 'Clinical', 'Pharmacokinetics', 'Clinical Drug Supply Management', 'Statistics', 'Bioanalysis', '202']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix C. Study Activities', 'Category previously read:', 'Survival', 'Non-Treatment', 'End of', 'FU', 'Screening', 'Treatment (Each Cycle)', 'Cycle Visit', 'Treatment', 'PTFUC', '(OS)d', 'Weekly', 'Within 7 Days', '(Day 8, 15, 22,', 'of Decision to', 'q6', 'q6', 'Day -21 to', 'Day', 'Day 1e', 'Day', 'Day', 'Day', 'Day 22', 'Day', 'Day', 'Day 1', '29, ,36)', 'Discontinue', 'Weeks', 'Weeks', 'Category', 'Description', 'Day -1', '-1', '(-3d)', '2', '8', '15', '(-3d)', '29', '36', '(=3d)', '(=3d)', 'Treatment', '(+1wk)', '(+1wk)', 'Safety', 'Echocardiogram\u00b2', 'X', 'X', 'Assessments', 'Has been changed to read:', 'Survival', 'Non-Treatment', 'End of', 'FU', 'Screening', 'Treatment (Each Cycle)', 'Cycle Visit', 'Treatmentb', 'PTFU', '(OS)', 'Weekly', 'Within 7 Days', '(Day 8, 15, 22,', 'of Decision to', 'q6', 'q6', 'Day -21 to', 'Day', 'Day 1e', 'Day', 'Day', 'Day', 'Day 22', 'Day', 'Day', 'Day 1', '29,36)', 'Discontinue', 'Weeks', 'Weeks', 'Category', 'Description', 'Day -1', '-1', '(-3d)', '2', '8', '15', '(-3d)', '29', '36', '(=3d)', '(=3d)', 'Treatment', '(1wk)', '(+1wk)', 'Safety', 'Echocardiogram\"', 'X', 'X', 'X', 'Assessments', '203']\n\n###\n\n", "completion": "END"}